<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25054764</article-id>
      <article-id pub-id-type="pmc">4148291</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20142955</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>What is your Diagnosis?</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case for diagnosis<sup><xref ref-type="fn" rid="fn01">*</xref></sup>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Maquin&#xE9;</surname>
            <given-names>Gustavo &#xC1;vila</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maroja</surname>
            <given-names>Maria de F&#xE1;tima</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Cristina Rabello</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Sousa</surname>
            <given-names>Petra Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Morais</surname>
            <given-names>Patr&#xED;cia Motta</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Talhari</surname>
            <given-names>Carolina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> "Alfredo da Matta" Foundation (FUAM) - Manaus (AM), Brazil.</aff>
      <aff id="aff02"><label>2</label> Santa J&#xFA;lia Hospital - Manaus (AM), Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Gustavo &#xC1;vila Maquin&#xE9;, Rua Codaj&#xE1;s 24 -
Cachoeirinha, 69065-130 - Manaus - AM, Brazil. E-mail:
<email>gustavo_maquine@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>4</issue>
      <fpage>675</fpage>
      <lpage>676</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report the case of a 81-year-old female patient who had a two-year history of
violet-colored erythematous tumors on both legs. Histopathological and
immunohistochemical examinations confirmed the diagnosis of primary cutaneous
large B-cell lymphoma, leg type. This rare, cutaneous lymphoma affects
predominantly elderly females. Clinically, patients present with tumoral lesions
on one or both legs (worst prognosis). Diagnosis is based on clinical,
histopathological and immunohistochemical findings. The strong expression of
BCL2, BCL6, MUM-1 and CD20, and the positivity for Ki67 antigen confirm the
diagnosis. R-CHOP chemotherapy regimen (rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisone) is the most widely accepted
treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>B-cell lymphomas</kwd>
        <kwd>Legs</kwd>
        <kwd>Combination chemotherapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>CASE REPORT</title>
      <p>A 81-year-old female patient had a 2-year history of painful lesions on both legs.
She complained of asthenia, decreased appetite and changes in the sleep-wake cycle.
Physical examination evidenced multiple brownviolet nodular lesions on both legs.
Some of the lesions were ulcerated, with drainage of purulent and serosanguineous
secretion (<xref ref-type="fig" rid="f01">Figure 1</xref>). There was non-pitting
edema extending throughout the length of the legs. During hospitalization, atrial
flutter and decompensated heart failure were diagnosed. Histopathological
examination showed extensive dermal infiltration by malignant neoplasm of large
cells with voluminous, irregular nuclei, prominent nucleoli and scant cytoplasm
(<xref ref-type="fig" rid="f02">Figure 2</xref>). Immunohistochemistry showed
strong expression of CD20, negativity for CD3, and high levels (&gt;80%) of Ki67
index of cell proliferation (<xref ref-type="fig" rid="f03">Figure 3</xref>).
Computed tomography of the abdomen and thorax showed no abnormalities.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p><bold>A.</bold> Violet-colored erythematous nodular lesions with central
ulceration on the anteromedial region of the right leg; <bold>B.</bold> More
abundant, similar lesions on the anterior region of the left leg</p>
        </caption>
        <graphic xlink:href="abd-89-04-0675-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A.</bold> Tumor infiltrate involving the whole dermis and presence of
Grenz zone; <bold>B.</bold> Cells with pleomorphic hyperchromatic nuclei
seen in more detail</p>
        </caption>
        <graphic xlink:href="abd-89-04-0675-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p><bold>A.</bold> Positive immunohistochemistry for CD20; <bold>B.</bold> High
levels (&gt;80%) of Ki67 index of cell proliferation</p>
        </caption>
        <graphic xlink:href="abd-89-04-0675-g03"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The diagnosis of primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT) was
confirmed by clinical, histological and immunohistochemistry findings. These
lymphomas are malignancies of the lymphoreticular system that originate from three
lymphoid cells lines: B, T and NK (natural killer). Primary cutaneous lymphomas are
neoplasias restricted to the skin. According to the WHO-EORTC classification (2008),
cutaneous B-cell lymphomas are classified into three types: marginal zone primary
cutaneous B-cell lymphoma; centrofolicular primary cutaneous lymphoma and PCLBCL-LT.
The PCLBCL-LT corresponds to 4% of all cutaneous lymphomas and to 20% of all primary
B-cell lymphomas.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> Clinically, it presents itself as single or
multiple violet-colored erythematous tumors on one or both legs. Affection of the
lymph node, bone marrow and central nervous system may rarely occur in PCLBCL-LT.
The five-year survival is 50%.<sup><xref rid="r03" ref-type="bibr">3</xref>-<xref rid="r05" ref-type="bibr">5</xref></sup> Histological examination of tumor
lesions shows a diffuse, monotonous cellular infiltrate of immunoblasts, without
epidermotropism. The presence of the normal collagen band in the superficial dermis,
separating the epidermis from the dermal lymphocytic infiltrate (Grenz zone) is a
common finding in cutaneous B-cell lymphomas. Neoplastic cells are positive for
CD20, CD79a and negative for CD3. There is strong expression of BCL-2, BCL-6 and
MUM-1. Anti-Ki67 antibodies are also an important aid in the diagnosis of B-cell
lymphoproliferative processes.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> Currently, the R-CHOP chemotherapy regimen (rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely
accepted treatment for PCLBCL-LT.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> The alternative COP chemotherapy regimen (cyclophosphamide,
vincristine and prednisone) was chosen due to the presence of heart failure (which
contraindicates the use of doxorubicin), the delay in the release of the
immunohistochemistry examination results (required for the release of rituximab),
and, especially, the rapid progression of the disease. There was a partial
regression of cutaneous lesions and reduction of cutaneous infiltration after the
first cycle of chemotherapy. However, the patient acquired nosocomial pneumonia,
progressed to septic shock and died four months after the diagnosis of
PCLBCL-LT.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Study conducted at the "Alfredo da Matta" Foundation (FUAM) - Manaus (AM),
Brazil.</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Maquin&#xE9; GA, Maroja MF, Mesquita CR, Souza PP, Morais
PM, Talhari C. Case for diagnosis. Primary cutaneous large B-cell lymphoma, leg
type. An Bras Dermatol. 2014;89(4):675-6.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cerroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Berti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>WHO-EORTC classification for cutaneous lymphomas</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <fpage>3768</fpage>
          <lpage>3785</lpage>
          <pub-id pub-id-type="pmid">15692063</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Primary cutaneous lymphomas</article-title>
          <source>Ann Oncol</source>
          <year>2011</year>
          <volume>22</volume>
          <fpage>72</fpage>
          <lpage>75</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hristov</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Primay cutaneous diffuse large B-cell lymphoma, leg type:
diagnostic considerations</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2012</year>
          <volume>136</volume>
          <fpage>876</fpage>
          <lpage>881</lpage>
          <pub-id pub-id-type="pmid">22849734</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bessell</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Humber</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>PD</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.:
prognosis of subtypes defined in the WHO-EORTC
classification</article-title>
          <source>Br J Dermatol</source>
          <year>2012</year>
          <volume>167</volume>
          <fpage>1118</fpage>
          <lpage>1123</lpage>
          <pub-id pub-id-type="pmid">22759204</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Cwynarski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gldstone</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <chapter-title>Non-Hodgkin lymphoma</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Hoffbrand</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Catovsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tuddenham</surname>
            </name>
            <name>
              <surname>Edward</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
          <source>Postgraduate Haematology</source>
          <edition>6th ed</edition>
          <publisher-loc>Oxford, UK</publisher-loc>
          <publisher-name>Willey-Blackwell</publisher-name>
          <year>2011</year>
          <fpage>655</fpage>
          <lpage>685</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moricz</surname>
              <given-names>CZM</given-names>
            </name>
            <name>
              <surname>Sanches</surname>
              <given-names>JA</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Part 1 - Primary cutaneous B-cell lymphomas</article-title>
          <source>An Bras Dermatol</source>
          <year>2005</year>
          <volume>80</volume>
          <fpage>461</fpage>
          <lpage>471</lpage>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grange</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Beylot-Barry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Courville</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maubec</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bagot</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vergier</surname>
              <given-names>B</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Clinicopathologic Features and Prognostic Analysis in 60
Cases</article-title>
          <source>Arch Dermatol</source>
          <year>2007</year>
          <volume>143</volume>
          <fpage>1144</fpage>
          <lpage>1150</lpage>
          <pub-id pub-id-type="pmid">17875875</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Gaynor</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Dahlberg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Oken</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Mize</surname>
              <given-names>EM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Comparison of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin's lymphoma</article-title>
          <source>N Engl J Med</source>
          <year>1993</year>
          <volume>328</volume>
          <fpage>1002</fpage>
          <lpage>1006</lpage>
          <pub-id pub-id-type="pmid">7680764</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sehn</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chhanabhai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Klasa</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Introduction of combined CHOP plus rituximab therapy dramatically
improved outcome of diffuse large B-cell lymphoma in British
Columbia</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>5027</fpage>
          <lpage>5033</lpage>
          <pub-id pub-id-type="pmid">15955905</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
